Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04644068 · ClinicalTrials.gov registry record · Phase 1

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
702
Enrollment target
20
Study locations

NCT04644068 is a Phase 1 study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 702 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04644068, a Phase 1 study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
702 participants
Enrollment target
20
Study locations

Study Summary

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions Studied

Breast Cancer Prostate Cancer Non-Small Cell Lung Cancer Colorectal Cancer Ovarian Cancer Pancreatic Cancer Bladder Cancer Gastric Cancer Biliary Cancer Additional Indications Below for Module 4 and 5

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG Dato-DXd
  • DRUG AZD5305
  • DRUG T- Dxd

Study Locations (20)

Other

  • Research Site - Heidelberg
  • Research Site - Melbourne
  • Research Site - Beijing
  • Research Site - Changchun
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Chongqing
  • Research Site - Guangzhou
  • Research Site - Harbin
  • Research Site - Jining
  • Research Site - Shandong

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

Quebec

  • Research Site - Montreal
  • Research Site - Montreal

New York

  • Research Site - New York

Oklahoma

  • Research Site - Oklahoma City

Texas

  • Research Site - Houston

British Columbia

  • Research Site - Vancouver

Ontario

  • Research Site - Toronto

Trial Details

FieldValue
Enrollment Target 702 participants
Start Date 2020-11-12
Est. Completion 2027-05-28
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04644068

The ClinicalTrials.gov registry entry for NCT04644068 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 702 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (75% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04644068 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Massachusetts, Quebec.

Frequently Asked Questions

What is clinical trial NCT04644068 about?

NCT04644068 is a clinical study titled "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies". This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

What is the current status of trial NCT04644068?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 702 participants. The study started on 2020-11-12. Estimated completion is 2027-05-28.

What conditions does trial NCT04644068 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer.

What interventions are being tested in trial NCT04644068?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Dato-DXd (DRUG), AZD5305 (DRUG), T- Dxd (DRUG).

Who is sponsoring clinical trial NCT04644068?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04644068 being conducted?

This trial has 20 study locations across Massachusetts, New York, Oklahoma, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Prostate Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.